Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407

INTRODUCTION: Pembrolizumab plus chemotherapy significantly improved survival outcomes versus placebo plus chemotherapy in patients with previously untreated metastatic squamous NSCLC in the randomized, double-blind, phase 3 KEYNOTE-407 study. We present the results of Chinese patients enrolled in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, Zhang, Li, Hu, Jie, Wang, Donglin, Hu, ChengPing, Zhou, Jianying, Wu, Lin, Cao, Lejie, Liu, Jiwei, Zhang, Helong, Sun, Hong, Wang, Ziping, Gao, Hongjun, Sun, Yuping, Li, Ben, Hu, Xiaohan, Schwarzenberger, Paul, Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503629/
https://www.ncbi.nlm.nih.gov/pubmed/34661177
http://dx.doi.org/10.1016/j.jtocrr.2021.100225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503629/
https://www.ncbi.nlm.nih.gov/pubmed/34661177
http://dx.doi.org/10.1016/j.jtocrr.2021.100225

Ejemplares similares